Analyst Research

Report Title Price
Provider: Reuters Investment Profile
Provider: Thomson Reuters Stock Report
Provider: Ford Investor Services, Inc.
Provider: ValuEngine, Inc.

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Achillion Pharmaceuticals Inc Names Milind Deshpande, Ph.D., As President, Chief Executive Officer, Following Announced Retirement Of Michael Kishbauch

Tuesday, 28 May 2013 04:05pm EDT 

Achillion Pharmaceuticals Inc announced that President and Chief Executive Officer Michael D. Kishbauch has decided to retire. In conjunction with this decision, the Board has appointed President of Research and Development and Chief Scientific Officer, Milind Deshpande, Ph.D., to the role of President and Chief Executive Officer and to the Board of Directors. Mr. Kishbauch, who will continue working with management over a three month transition period, will remain a Director on the Achillion Board and is being appointed Chair of a newly-formed Strategy and Corporate Development Committee of the Board. 

Company Quote

0.06 +0.60%
24 Apr 2015